Physician profile
Michael Brown
NPI 1235101825
$1,665.40
in general payments reported to CMS, 2019-2025
27 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.60 · 2022: $127 · 2023: $174 · 2024: $590 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $351.24 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $145.80 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $122.43 | 2024-2025 | Xtandi, Vyloy, Padcev |
| Novocure INC. | $121.88 | 2021-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Lilly USA, LLC | $102.93 | 2022-2024 | Verzenio |
| Abbvie INC. | $70.20 | 2025 | |
| Amgen INC. | $64.95 | 2022-2025 | Vectibix, Kyprolis |
| Genentech USA, INC. | $53.39 | 2025 | Itovebi, Polivy |
| Karyopharm Therapeutics INC. | $44.70 | 2024-2025 | Xpovio |
| Pfizer INC. | $44.37 | 2022-2024 | |
| Syndax Pharmaceuticals, INC. | $43.65 | 2025 | Revuforj |
| Progenics Pharmaceuticals, INC. | $43.20 | 2023-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $42.97 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $41.50 | 2024 | Iclusig, Ninlaro |
| Pharmacosmos Therapeutics INC. | $37.01 | 2025 | Monoferric |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.67 | 2024 | |
| Glaxosmithkline, LLC. | $35.37 | 2024 | Jemperli, Zejula |
| Emd Serono, INC. | $32.89 | 2024 | |
| Stemline Therapeutics INC. | $32.60 | 2024-2025 | Elzonris |
| Coherus Oncology, INC. | $29.09 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.76 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $26.56 | 2023 | Enhertu |
| Taiho Oncology, INC. | $26.03 | 2024 | |
| Gilead Sciences, INC. | $23.47 | 2024 | |
| Myriad Genetic Laboratories, INC. | $22.28 | 2025 | Prolaris |
| Exelixis INC. | $22.25 | 2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $21.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.